The importance of angiogenesis (and its interplay with the tumor immune microenvironment [TME]) is evident by recent data showing that a combination of bevacizumab (anti-VEGFA) and atezolizumab (anti-programmed cell death ligand 1 [PD-L1]) antibodies improved survival in patients with advanced unresectable HCC.5 The gene discussed is VEGFA; the disease is neoplasm.